**Proteins** 

## **Product** Data Sheet

### L-DABA

Cat. No.: HY-101414 CAS No.: 1758-80-1 Molecular Formula:  $C_{4}H_{10}N_{2}O_{2}$ Molecular Weight: 118.13

Target: GABA Receptor; Endogenous Metabolite

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling; Metabolic Enzyme/Protease

-20°C Storage: Powder 3 years

> 4°C 2 years

-80°C In solvent 2 years

> -20°C 1 year

# $NH_2$

#### **SOLVENT & SOLUBILITY**

In Vitro

H<sub>2</sub>O: 1 mg/mL (8.47 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	8.4653 mL	42.3263 mL	84.6525 mL
	5 mM	1.6931 mL	8.4653 mL	16.9305 mL
	10 mM			

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 100 mg/mL (846.53 mM); Clear solution; Need ultrasonic

#### **BIOLOGICAL ACTIVITY**

Description L-DABA (L-2,4-Diaminobutyric acid) is a week GABA transaminase inhibitor with an IC<sub>50</sub> of larger than 500 μM; exhibits antitumor activity in vivo and in vitro.

IC<sub>50</sub> & Target Human Endogenous Metabolite

In Vitro

The tumor cells are irreversibly and totally damaged by incubation with 10 mM L-2,4-Diaminobutyric acid for 24 h at 37°C. The cell-destructive effect by L-DABA is probably due to an osmotic lysis induced by the non-saturated intracellular accumulation of L-DABA. The harmful effect of L-DABA could be abolished by concomitant incubation with L-alanine and L $methionine^{[1]}$ . Kinetic studies indicates that L-DABA is a non-linear, non-competitive inhibitor of GABA transaminase activity. The L-DABA-induced elevation of GABA levels parallels the inhibition of GABA transaminase activity<sup>[2]</sup>. L-2,4-Diaminobutyric acid, an amino acid analogue, produceS a cytolytic effect with a human glioma cell line, SKMG-1, and normal human fibroblasts. The concentrations of L-DABA necessary to reduce the cell count to 50% of control following a

	24-h incubation at 37°C are 12.5 mM for the human fibroblasts and 20 mM for the glioma cell line <sup>[3]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Treatment with L-DABA results in 43.4% reduction of tumor growth <sup>[1]</sup> . L-DABA is a more effective inhibitor of GABA transaminase in vivo than in vitro <sup>[2]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **PROTOCOL**

Animal
Administration [2]

Mice: Male Sprague Dawley rats (150-200g) are used in the study. LDABA is dissolved in 09.% saline and diluted in appropriate medium. L-DABA is administered intraperitoneally at a dose of 764 mg/kg in a volume of 4 mL/kg in acute studies. Chronically treated rats receives daily intraperitoneally injections (2.5mM/kg in saline) for 3 days. Mice are sacrificed and the brain regions are dissected for analysis<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

- [1]. Ronquist G, et al. Antitumor activity of L-2,4 diaminobuturic acid against mouse fibrosarcoma cells in vitro and in vivo. J Cancer Res Clin Oncol. 1980;96(3):259-68.
- [2]. Beart PM, et al. l-2,4-Diaminobutyric acid and the GABA system. Neurosci Lett. 1977 Jul;5(3-4):193-8.
- [3]. Panasci L, et al. The cytolytic effect of L-2,4 diaminobutyric acid with malignant glioma cells and fibroblasts. Cancer Chemother Pharmacol. 1988;21(2):143-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA